GSK’s COX-2 Plans: Complete Cardio Safety Study, Test Efficacy Of Low Doses

02 May 2005

• By The Pink Sheet

GlaxoSmithKline is pushing back the anticipated NDA filing date for its Phase II COX-2 inhibitor to complete a cardiovascular safety study at the request of FDA, CEO J.P. Garnier said during an earnings call April 28

GSK’s COX-2 Plans: Complete Cardio Safety Study, Test Efficacy Of Low Doses

More from Archive

More from Pink Sheet